{"id":305060,"date":"2025-12-15T00:00:00","date_gmt":"2025-12-15T00:00:00","guid":{"rendered":"http:\/\/clarivate.com\/life-sciences-healthcare\/report\/dlsfcg0004-2024-biopharma-multiple-sclerosis-landscape-forecast-disease-landscape-forecast-g7\/"},"modified":"2026-03-31T10:23:59","modified_gmt":"2026-03-31T10:23:59","slug":"dlsfcg0004-2026-biopharma-multiple-sclerosis-landscape-forecast-disease-landscape-forecast-g7","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/dlsfcg0004-2026-biopharma-multiple-sclerosis-landscape-forecast-disease-landscape-forecast-g7\/","title":{"rendered":"Multiple Sclerosis &#8211; Landscape &#038; Forecast &#8211; Disease Landscape &#038; Forecast (G7)"},"content":{"rendered":"<p>The market for multiple sclerosis (<abbr data-abbreviation-entity=\"4900\" title=\"multiple sclerosis\">MS<\/abbr>) disease-modifying therapies (<abbr data-abbreviation-entity=\"5066\" title=\"disease-modifying therapy\">DMT<\/abbr>s) is crowded and competitive, as TG Therapeutics \/ Neuraxpharm\u2019s Briumvi (ublituximab), Novartis\u2019s Kesimpta (ofatumumab), and Roche\u2019s subcutaneous Ocrevus Zunovo heighten competition in the dominant anti-CD20 class. Despite clinical setbacks for some emerging <abbr data-abbreviation-entity=\"5619\" title=\"Bruton\u2019s tyrosine kinase\">BTK<\/abbr> inhibitors in relapsing <abbr data-abbreviation-entity=\"4900\" title=\"multiple sclerosis\">MS<\/abbr>, the class holds promise in underserved progressive <abbr data-abbreviation-entity=\"4900\" title=\"multiple sclerosis\">MS<\/abbr> populations, with key readouts for Sanofi\u2019s tolebrutinib and Roche\u2019s fenebrutinib coming in 2025. With oral generics a reality in the United States and Europe, the first biosimilar (i.e., Sandoz\u2019s Tyruko [natalizumab-sztn]) has also launched and others are expected to reach market before 2034. Understanding and navigating these market dynamics will be crucial for the success of both current and future players in this evolving landscape.<\/p>\n<p><strong>Questions answered: <\/strong><\/p>\n<ul class=\"round-bullets\">\n<li>What is the commercial outlook for emerging oral <abbr data-abbreviation-entity=\"5619\" title=\"Bruton\u2019s tyrosine kinase\">BTK<\/abbr> inhibitors in relapsing and progressive forms of <abbr data-abbreviation-entity=\"4900\" title=\"multiple sclerosis\">MS<\/abbr> given current clinical evidence?<\/li>\n<li>What commercial impact could Sanofi\u2019s frexalimab have for both relapsing and nonrelapsing <abbr data-abbreviation-entity=\"4962\" title=\"secondary-progressive multiple sclerosis\">SP-MS<\/abbr> patients?<\/li>\n<li>How will Briumvi, Kesimpta, and Ocrevus Zunovo impact the use of Ocrevus in the relapsing and progressive <abbr data-abbreviation-entity=\"4900\" title=\"multiple sclerosis\">MS<\/abbr> markets?<\/li>\n<li>What do key opinion leaders think about emerging agents for relapsing and progressive <abbr data-abbreviation-entity=\"4900\" title=\"multiple sclerosis\">MS<\/abbr> patients, and what is the commercial outlook for these therapies?<\/li>\n<\/ul>\n<p><strong>Markets covered:<\/strong> United States, France, Germany, Italy, Spain, United Kingdom, Japan<\/p>\n<p><strong>Primary research: <\/strong>Country-specific interviews with thought-leading neurologists; survey data collected for this and other Clarivate research<\/p>\n<p><strong>Epidemiology: <\/strong>Diagnosed and drug-treated prevalence of total <abbr title=\"multiple sclerosis\">MS<\/abbr>, <abbr data-abbreviation-entity=\"4764\" title=\"clinically isolated syndrome\">CIS<\/abbr>, <abbr title=\"relapsing-remitting multiple sclerosis\">RR-MS<\/abbr>, <abbr title=\"secondary-progressive multiple sclerosis\">SP-MS<\/abbr>, and <abbr title=\"primary-progressive multiple sclerosis\">PP-MS<\/abbr><\/p>\n<p><strong>Drug treatments:<\/strong> Coverage of key current and late-phase emerging therapies<\/p>\n<p><strong>Forecast:<\/strong> 10-year, annualized, drug-level sales and patient share of key <abbr data-abbreviation-entity=\"4900\" title=\"multiple sclerosis\">MS<\/abbr> therapies through 2034, segmented by brands \/ generics and epidemiological subpopulations<\/p>\n<p><strong>Product description<\/strong><\/p>\n<p>Disease Landscape &#038; Forecast offers comprehensive market intelligence with world-class epidemiology, keen insight into current and emerging therapies, and drug forecasts supported by detailed primary and secondary research, enabling you to:<\/p>\n<ul class=\"round-bullets\">\n<li>Optimize your long-term disease and development strategy.<\/li>\n<li>Quantify market potential for your pipeline assets and those of your competitors.<\/li>\n<li>Understand a disease from top to bottom, including key patient populations, the current and future therapeutic landscape, and the evolving market trajectory.<\/li>\n<li>Gauge the commercial outlook and impact of key market events.<\/li>\n<\/ul>\n","protected":false},"template":"","class_list":["post-305060","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-multiple-sclerosis","biopharma-therapy-areas-neurology","biopharma-date-2297"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/305060","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":10,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/305060\/revisions"}],"predecessor-version":[{"id":575258,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/305060\/revisions\/575258"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=305060"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}